Active	Status	Sponsor type	Region	Phase	Filter
48 Active 16 Inactive 64 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

18 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Li, Yan
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis Safety and efficacy data from LUCENT-2 trial for ulcerative colitis Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis	Active, not recruiting	3	1177	Europe, Canada, Japan, US, RoW	Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC	Eli Lilly and Company	Ulcerative Colitis	11/21	12/24
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy	Active, not recruiting	3	380	Europe, Canada, Japan, US, RoW	Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo	Chinook Therapeutics U.S., Inc.	IgA Nephropathy, Immunoglobulin A Nephropathy	09/23	12/26
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer	Active, not recruiting	3	274	RoW	BPI-16350, placebo, Fulvestrant	Betta Pharmaceuticals Co., Ltd.	Breast Cancer	12/23	07/25
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients With Neovascular Age-related Macular Degeneration	Recruiting	3	488	RoW	TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis	TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.	Neovascular Age-related Macular Degeneration	03/24	03/24
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time	Completed	3	928	Europe, Canada, Japan, US, RoW	Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec	Eli Lilly and Company	Diabetes, Type 2 Diabetes	04/24	04/24
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL	Recruiting	3	218	RoW	ICP-022, Chlorambucil, Rituximab	Beijing InnoCare Pharma Tech Co., Ltd.	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	12/24	06/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
NCT06083623: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants	Not yet recruiting	2b	2250	RoW	TNM001, placebo	Zhuhai Trinomab Pharmaceutical Co., Ltd.	Respiratory Syncytial Virus Infections	05/26	08/26
NCT05299697: A Study of TG103 Injection in Overweight or Obesity	Recruiting	2	195	RoW	TG103 15 mg, TG103 22.5 mg, Placebo	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	Overweight or Obesity	06/23	09/23
NCT06206720: A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV	Recruiting	2	60	RoW	Deuremidevir Hydrobromide for Suspension, VV116, Placebo, VV116 placebo	Vigonvita Life Sciences	Respiratory Syncytial Virus Infection	09/24	12/24
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus	Not yet recruiting	2	318	RoW	HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Type 2 Diabetes	04/25	04/25
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases	Active, not recruiting	2	103	Europe, US, RoW	Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627	Chinook Therapeutics U.S., Inc.	IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy	07/24	07/26
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)	Recruiting	1/2	39	RoW	400mg of TQB3909 tablets, 600mg of TQB3909 tablets	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	Mantle Cell Lymphoma	12/24	12/24
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia	Recruiting	1/2	90	RoW	BN104	BioNova Pharmaceuticals (Shanghai) LTD.	ALL, Adult, AML, Adult	06/26	06/27
NCT05480592: A Study of HS-10380 in Chinese Participants	Recruiting	1	76	RoW	HS-10380, Placebo	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Schizophrenia	06/23	07/23
INFINITE, NCT04328662: A Study of Ninlaro in Real World Clinical Practice in China	Active, not recruiting	N/A	482	RoW		Takeda	Multiple Myeloma, Neoplasms, Plasma Cell	09/25	09/25
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System	Not yet recruiting	N/A	2150	RoW	Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy	Lepu Medical Technology (Beijing) Co., Ltd.	Coronary Heart Disease	01/26	01/28